Nav: Home

Multiple sclerosis: Reduced levels of contrast agent deposits in the brain

December 12, 2016

Gadolinium, one of the rare earth elements, is used as a contrast agent that enhances the quality of MRI examinations of internal organs and tissues. Researchers from Charité - Universitätsmedizin Berlin (NeuroCure Clinical Research Center and Department of Radiology) and the Max Delbrück Center for Molecular Medicine, have studied the extent to which repeated use of gadolinium-based MRI contrast agents leads to gadolinium deposition in the brains of patients with multiple sclerosis. Their report, which has recently been published in the Multiple Sclerosis Journal*, suggests that the risk of such accumulations occurring is reduced if contrast agents known as 'macrocylcic agents' are used.

Research conducted over the past few years has shown that the use of gadolinium-based MRI contrast agents can lead to permanent deposits in certain areas of the brains of patients undergoing MR imaging. There is currently no evidence to suggest that these deposits pose a heath risk. However, evidence regarding the existence of gadolinium deposition in different brain regions has caused uncertainty and concern among patients and physicians. The issue of gadolinium deposition is of particular relevance to patients with multiple sclerosis (MS). This is because patients usually develop symptoms as young adults, and go on to have a relatively high number of contrast-enhanced MRI scans during their lives.

Under the leadership of PD Dr. Michael Scheel and Prof. Dr. Friedemann Paul, a team of researchers studied the use of two different types of commonly-used MRI contrast agents. Results from their research were able to confirm what previous studies have shown in other patient groups; namely, that the repeated use of a certain type of linear contrast agent leads to deposits in a key area of the cerebellum. "Patients who received a different type of MRI contrast agent - one that is referred to as a macrocyclic contrast agent - showed no evidence of gadolinium brain deposition," explains PD Dr. Scheel. The researchers go on to add that "available data currently suggest that the risk of deposits is considerably higher with contrast agents that have a linear molecular structure. This effect appears to be absent, or much reduced, when using contrast agents with a ring-shaped, macrocyclic structure." With regard to the relevance of their results for future clinical practice, the researches have a clear recommendation: before performing contrast-enhanced MRI examinations in patients with MS, neurologists and radiologists should give due consideration to the findings of this study. At the Charité, only agents with a macrocyclic structure have been used as MRI contrast agents for several years.
-end-
*Ludwig Schlemm, Claudia Chien, Judith Bellmann-Strobl, Jan Dörr, Jens Wuerfel, Alexander U Brandt, Friedemann Paul and Michael Scheel. Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Mult Scler September 27, 2016. doi: 10.1177/1352458516670738. https://www.ncbi.nlm.nih.gov/pubmed/27679460

Contact:
PD Dr. Michael Scheel
NeuroCure Cluster of Excellence
and Radiology Department, Charité - University Medicine Berlin and Max Delbrueck Center for Molecular Medicine
Tel: +49 30 450 627 173
Email: michael.scheel@charite.de

Link: NeuroCure

Charité - Universitätsmedizin Berlin

Related Multiple Sclerosis Articles:

New biomarkers of multiple sclerosis pathogenesis
Multiple sclerosis (MS) is a chronic debilitating inflammatory disease targeting the brain.
Using telemedicine to treat multiple sclerosis
Multiple sclerosis (MS) clinicians face continued challenges in optimizing neurological care, especially for people with advanced MS living in medically underserved communities.
Improving symptom tracking in multiple sclerosis
With a recent two-year, $833,000 grant from the US Department of Defense, kinesiology professor Richard van Emmerik and colleagues at the University of Massachusetts Amherst hope to eventually help an estimated 1 million people worldwide living with progressive multiple sclerosis by creating an improved diagnostic test for this form of the disease, which is characterized by a steady decrease in nervous system function.
An antibody-based drug for multiple sclerosis
Inserm Unit U919, directed by Professor Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis.
Four new risk genes associated with multiple sclerosis discovered
Scientists of the Technical University of Munich and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis.
PET detects neuroinflammation in multiple sclerosis
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
Scientists find genetic cause of multiple sclerosis
Researchers have discovered a rare genetic mutation that makes it probable that a person will develop multiple sclerosis (MS).
ANKRD55: A new gene involved in Multiple Sclerosis is discovered
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55.
Children with and without multiple sclerosis have differences in gut bacteria
In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease.
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

Related Multiple Sclerosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.